ALGN

Align's $37.5M U.K. VAT liability, new 20% VAT charges and pending appeal add fresh earnings uncertainty amid currency and mix pressures.

ALGN's record Clear Aligner growth and global adoption support the bull case, but demand softness and scanner pricing pressure keep investors cautious.

SAN JOSE, Calif. & TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. ("Align") (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, today announced that the Jinan Intermediate People's Court in China issued a judgment in favor of Align in a patent infringement action against Angelalign Technology's operating subsidiaries in China ("Angel") (Hong Kong Stock Exchange: 6699.HK). In September 2025, Align filed a.

Align Technology delivers record revenue, volume, and operating margins, yet trades near five-year valuation lows despite structural business improvements. Competitive pressures have eased post-SmileDirectClub exit, with ALGN retaining dominant market share and shifting growth toward international and DSO channels. Operating margins are expanding, management continues to raise guidance, and a robust buyback program is underway, supported by strong free cash flow.

Align Technology delivered record Q2 revenue and clear aligner volumes, with robust international growth offsetting North American stagnation. ALGN's strategy centers on expanding its digital dentistry platform, leveraging financing, lower-cost products, and ecosystem growth to drive recurring revenue. Valuation at $173 per share (15–16x forward earnings) is attractive for a market leader with high margins, net cash, and ongoing share buybacks.

Align Technology shares rise after Q2 earnings and revenues beat estimates, fueled by record Clear Aligner shipments and wider non-GAAP margins.

ALGN highlights record clear aligner volumes, digital workflow expansion and margin gains while balancing scanner pricing pressures and long-term growth plans.

Align Technology said on Wednesday it will add three new ​independent directors to its board and launch ‌a review of its operations, following talks with activist investor Elliott Investment Management.

TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (“Align”) (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced several initiatives reflecting its commitment to strong corporate governance and shareholder value creation. Following discussions with Elliott Investment Management L.P. (toge.

TEMPE, Ariz & SAN JOSE, Calif.--(BUSINESS WIRE)--Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today introduced new innovations across its integrated Align™ Digital Platform*, designed to help doctors visualize, plan, and treat with greater confidence and predictability. Throug.